+1,298.7%
CRDO vs GSK
+30.4%
+1,268.3%
-62.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | 0.0% | +1.6% | +1.6% |
| 7D | -4.5% | -3.5% | -0.9% | -4.5% |
| 30D | -39.2% | -3.4% | -35.8% | -39.3% |
| 3M | -38.5% | -8.1% | -30.3% | -38.5% |
| 6M | +40.6% | -11.1% | +51.7% | +40.8% |
| YTD | +13.2% | +0.7% | +12.5% | +12.1% |
| 1Y | +2.3% | +20.1% | -17.9% | -1.2% |
| 3Y | +942.5% | +46.1% | +896.4% | +839.2% |
| All | +1,298.7% | +30.4% | +1,268.3% | +1,270.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling